43 results about "Swine influenzavirus" patented technology

The present invention relates to Equine Herpes Virus (EHV) vectors comprising at least one exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein said exogenous antigen encoding sequence is inserted into an insertion site, preferably ORF70, and said exogenous antigen encoding sequence is operably linked to a promoter sequence, preferably the promoter sequence comprising 4pgG600 (SEQ ID NO:1) or 4pMCP600 (SEQ ID NO:2) or the complementary nucleotide sequences thereof or a functional fragment or a functional derivative thereof or the complementary nucleotide sequences thereof. Furthermore, the present invention relates to methods for immunizing a food producing animal comprising administering to such food producing animal an immunogenic composition comprising embodiments of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal.

The invention discloses a nucleic-acid sequence-based amplification (NASBA) method for detecting a swine influenza virus (SIV). The NASBA method mainly comprises the following steps of: extracting the ribonucleic acid (RNA) from the SIV, preparing an NASBA system, preparing an NASBA program, carrying out identification on an NASBA product and carrying out PCR (Polymerase Chain Reaction) amplification. According to the NASBA method, the NASBA rapid detection method is established by taking the NP gene of the SIV as a target gene and is used for the diagnosis of the SIV. The method has higher specificity and sensitivity so as to detect a virus solution with the dilution factor of 10<-5>, so that the method can be used for the rapid detection of clinically-suspected SIV samples, meanwhile, the technical level of China in the diagnosis, epidemic surveillance, inspection and quarantine of swine influenza can be improved so as to ensure the healthful and rapid development of swine industry.

The invention discloses a breeding method for transgenic pigs expressing sIFITM3 (swine interferon induced transmembrane 3) genes. The breeding method comprises the steps as follows: firstly, the construction of swine fibroblast cell lines stably expressing the sIFITM3 genes comprises the following steps: the step a refers to the construction and the linearization of pcDNACAsIITM3 vectors, wherein, primers are designed, lymph node tissue RNA (Ribose Nucleic Acid) of pigs is extracted, the sIFITM3 genes are obtained through RT-PCR (Reverse Transcription-Polymerase Chain Reaction) amplification, ethanol precipitation is carried out, and sterile water is used for dissolving; the step b refers to liposome transfection, wherein, swine fibroblasts expressing sIFITM3 are constructed; the step c refers to screening and proliferation of nuclear donor cells transfected with the sIFITM3 genes; secondly, recombination blastula acquisition based on a manual nucleus transplantation method comprises the following steps: the step a refers to the preparation of recipient cells; the step b refers to enucleation and injection of the nuclear donor cells; and thirdly, the embryo transplantation and the acquisition of the transgenic pigs comprise the following steps: the step a refers to embryo transplantation, wherein, bred blastulas are transferred to a fallopian tube of a surrogate sow, and then detection is carried out; and the step b refers to transgenic individual identification. The breeding method is feasible, and is simple and convenient to operate; in addition, the pigs are the transgenic pigs expressing sIFITM3, and have the potential capability to resist animal virus such as foot-and-mouth disease virus, Japanese encephalitis virus, swine influenza virus and the like.

The invention relates to a vaccine composition for preventing and/or treating porcine circovirus diseases and swine influenza and its preparation method and use. The vaccine composition comprises i, a porcine circovirus subunit antigen or a nucleic acid which is used for coding the porcine circovirus subunit antigen and can be expressed in a pig, and ii, a swine influenza virus subunit antigen or a nucleic acid which is used for coding the swine influenza virus subunit antigen and can be expressed in a pig. The invention also relates to a nucleic acid molecule, a recombinant plasmid and a host cell for treating and/or preventing two types of pig diseases.

The invention belongs to the technical field of biology and discloses swine influenza virus H1N1 subtype HA-1 protein recombinant suipoxvirus and a preparation method thereof. An HA1 gene is designed and synthesized according to the gene sequence of HA1 of an A/swine/Shanghai/1/2005(H1N 1) strain of the swine influenza virus, and the gene is cloned in a suipoxvirus vector pUSZ11 to obtain a transfer vector pUSZ11/H1. The recombinant virus is a positive clone obtained by infecting and transfecting PK15 cells with the suipoxvirus and the transfer vector pUSZ11/H1 and performing homologous recombination. The recombinant suipoxvirus can express HA1 protein stably, and after infection with the virus, the cytopathy becomes regular, the toxic effect of the breeding virus is stabilized at 107TCID50/mL, the breeding virus can effectively stimulate the immune protect reaction of organisms and can be used in the preparation of medicines for preventing and/or treating infection with swine influenza virus H1N1 subtype.

The invention provides a hybridoma cell strain, and belongs to the technical field of monoclonal antibody (MAb) preparation. The hybridoma cell strain disclosed by the invention can secrete avian-likeH1N1 swine influenza virus HA protein MAb, and the obtained MAb has the characteristics of good specificity, high titer and the like. By utilizing the MAb and combining a peptide scanning technology,the linear epitope 216VSVGSS221 located on the HA protein is obtained through screening, and the epitope is highly conservative in the avian-like H1N1 virus. The MAb and the epitope can be obtained to be used for establishing immunological diagnosis methods of the avian-like H1N1 SIV or the antibody thereof, such as ELISA, colloidal gold and the like. The HA protein epitope information of the H1N1 SIV can be perfected by obtaining the epitope information, the structure and the function of the HA protein antigen can be better understood, and theoretical and technical supports are provided forpredicting the dynamic state of virus antigenic variation and better preventing and controlling epidemic diseases.

The invention relates to a gene chip for determination and drug resistance detection of influenza A virus. The preparation method of the gene chip comprises the steps of preparing a universal primer, preparing a subtype nucleic acid parting probe and a drug resistance probe, preparing an oligonucleotide chip, establishing an RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) system and establishing a hybrid system. The gene chip prepared by the method disclosed by the invention can be used for simultaneously determining five kinds of subtype influenza A viruses, including influenza A H1N1 influenza virus, seasonal H1N1 influenza virus, seasonal H3N2 influenza virus, poultry H5N1 influenza virus and swine H1N1 influenza virus. In addition, the gene chip can be used for prompting the condition that the influenza A virus is non-drug resistant, has the advantages of quickness, accuracy, high throughput and high specificity and can be used for providing guidance for monitoring, clinical diagnosis and treatment of the influenza viruses.

The invention belongs to the technical field of veterinary drug application, relates to a sulfated yeast beta glucan application in preparation of anti-animal-virus drugs and particularly relates to the application in preparation of anti-swine-flu viruses, porcine reproductive and respiratory syndrome viruses and porcine pseudorabies virus drugs. The sulfated yeast beta glucan application in preparation of the anti-animal-virus drugs has the advantages of being wide in antiviral spectrum, high in effective rate, safe and toxic-and-side-effect-free and residue-free, reducing or replacing utilization of antibiotics, belonging to a novel antiviral drug and having good application and development prospects.

The invention belongs to the technical field of biology, and particularly relates to a crystal of African swine fever virus (ASFV) DNA ligase, and a preparation method and application of the crystal.The DNA ligase AsfvLIG contains 419 amino acids, has the molecular weight of about 45 kDa, and has highly soluble expression in an expression strain Escherichia coli BL21 (DE3). A three-dimensional structure of the crystal is obtained by X-ray diffraction, with the resolution reaching 2.5 angstroms. A crystallographic asymmetric unit has a protein molecule consisting of 9 alpha helixes and 17 betapleated sheets, and is combined with DNA of a catalytic reaction substrate. The 153th asparagine, the 211th leucine, the 402th leucine and the 403th glutamine in the structure have different conformations from human DNA ligase. The crystal structure of the DNA ligase AsfvLIG is widely used in drug design or drug screening for African swine fever viruses (ASFV).